<DOC>
	<DOCNO>NCT00001748</DOCNO>
	<brief_summary>Many patient hematological malignancy potentially curable bone marrow transplantation consider transplantation HLA identical family unrelated donor unavailable . For patient curative option transplant partially match family donor . Such transplant feasible less successful match sibling donor transplant . The main problem mismatch transplant graft rejection , graft-vs-host disease , regimen-related mortality . This restrict use mismatch transplant patient le 45 year high risk die hematological malignancy . This protocol evaluate new preparative regimen design ensure stem cell engraftment increase immunosuppression , follow G-CSF mobilize T cell deplete , stem cell rich , peripheral blood progenitor cell ( PBPC ) transplant mismatch related donor patient high risk hematological malignancy . This phase I study evaluates engraftment GVHD follow T cell deplete , HLA-mismatched PBPC transplant . Stopping rule use make modification protocol event graft failure . The end point study graft take , acute chronic GVHD , leukemic relapse , transplant-related mortality , death leukemia-free survival . Patients follow 5 year . It plan treat 35 patient age 10 45 year .</brief_summary>
	<brief_title>HLA-Mismatched Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation Hematological Malignancies</brief_title>
	<detailed_description>Many patient hematological malignancy potentially curable bone marrow transplantation consider transplantation HLA identical family unrelated donor unavailable . For patient curative option transplant partially match family donor . Such transplant feasible less successful match sibling donor transplant . The main problem mismatch transplant graft rejection , graft-vs-host disease , regimen-related mortality . This restrict use mismatch transplant patient le 45 year high risk die hematological malignancy . This protocol evaluate new preparative regimen design ensure stem cell engraftment increase immunosuppression , follow G-CSF mobilize T cell deplete , stem cell rich , peripheral blood progenitor cell ( PBPC ) transplant mismatch related donor patient high risk hematological malignancy . This phase I study evaluates engraftment GVHD follow T cell deplete , HLA-mismatched PBPC transplant . Stopping rule use make modification protocol event graft failure . The end point study graft take , acute chronic GVHD , leukemic relapse , transplant-related mortality , death leukemia-free survival . Patients follow 5 year . It plan treat 35 patient age 10 45 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Hematologic Neoplasms</mesh_term>
	<criteria>Patient : Ages 1045 year . Chronic myelogenous leukemia , category : accelerate phase blast transformation . Acute lymphoblastic leukemia , category : Adults ( great 18 year ) remission highrisk feature ( present leukocyte count great 100,000/cu mm , Karyotypes t9 ; 22 , t4 , t19 , t11 , biphenotypic leukemia ) . All second remission , primary induction failure include partial remission , partially respond untreated relapse . Acute myelogenous leukemia ( AML ) : All AML second subsequent remission , primary induction failure partial remission resistant relapse . Myelodysplastic syndrome , category : refractory anemia excess blast , transformation acute leukemia , chronic myelomonocytic leukemia . Myeloproliferative disorder undergo transformation terminal stage . Chronic lymphocytic leukemia ( CLL ) Richter transformation . Highgrade lymphoma , refractory standard treatment approach , mantle cell lymphoma . No major organ dysfunction preclude transplantation . DLCO great 65 % predict . Left ventricular ejection fraction : great 40 % predict . ECOG performance status 0 1 . Informed consent give . Informed consent parent minor . Women childbearing age negative pregnancy test may participate . Donor : Partially HLA match family donor ( 35/6 match ) . Fit receive GCSF give peripheral blood stem cell ( normal blood count , normotensive , history stroke ) . Informed consent give . Patients donor must pregnant nursing . Must ECOG performance status 2 . No severe psychiatric illness patient donor : Mental deficiency sufficiently severe make compliance BMT treatment unlikely make informed consent impossible . No major anticipate illness organ failure incompatible survival BMT . DLCO must less 65 % predict . No leave ventricular ejection fraction : le 40 % predict . Must serum creatinine great 3 mg/dl . Must serum bilirubin great 4 mg/dl , Transaminases great 3 time upper limit normal . Donor patient must HIV positive . Must history malignancy except basal cell squamous carcinoma skin , positive PAP smear subsequent negative follow . Donor must fit receive GCSF undergo apheresis . Must fail mobilize adequate number CD34+ cell two cycle GCSF .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 1999</verification_date>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Donor Apheresis</keyword>
	<keyword>Graft v . Host Disease</keyword>
	<keyword>Graft-Versus-Leukemia</keyword>
	<keyword>Leukemic Relapse</keyword>
	<keyword>Myeloma</keyword>
	<keyword>Peripheral Blood Stem Cells</keyword>
	<keyword>Whole Body Irradiation</keyword>
	<keyword>Acute Lymphoblastic Leukemia ( ALL )</keyword>
	<keyword>Chronic Lymphocytic Leukemia ( CLL )</keyword>
	<keyword>Chronic Myelogenous Leukemia ( CML )</keyword>
	<keyword>Hematological Malignancies</keyword>
	<keyword>Myelodysplastic Syndrome</keyword>
	<keyword>Myeloproliferative Disorders</keyword>
</DOC>